Department of Medicine and Scott & White Digestive Disease Research Center, Texas A&M HSC COM and Scott & White Hospital, Temple, TX 76504, USA.
J Hepatol. 2011 Dec;55(6):1339-45. doi: 10.1016/j.jhep.2011.04.015. Epub 2011 May 19.
BACKGROUND & AIMS: microRNAs (miRNAs) are a class of small noncoding RNAs that can regulate gene expression by translation repression or mRNA degradation. Our aim was to evaluate the role of aberrantly expressed miRNAs in hepatocellular cancer (HCC).
miRNA expression in HCC tissues and cells was evaluated by qPCR array and Taqman miRNA assay. Cell proliferation, motility, invasion, and the angiogenesis index were quantitated using commercial assays. DNA methylation status, matrix metalloproteinases (MMPs) mRNA expression was quantitated by real-time PCR analysis.
miRNA profiling identified a decrease in miR-125b expression in HCC tumor tissues and cell lines. The expression of miR-125b was significantly increased by the methylation inhibitor 5-aza-2'-deoxycytidine in HCC cells but not in normal controls, suggesting that the expression of miR-125b could be epigenetically modulated. Methylation-specific PCR revealed hypermethylation status of miR-125b in HCC cells compared to non-malignant controls. Cell proliferation, anchorage-independent growth, cell migration, invasion, and angiogenesis were significantly decreased by the introduction of miR-125b precursor in HCC cell lines. Placenta growth factor was identified as a target of miR-125b by bioinformatics analysis and experimentally verified using luciferase reporter constructs. Overexpression of miR-125b in HCC cells decreased PIGF expression, and altered the angiogenesis index. Furthermore, modulation of miR-125b also distorted expression of MMP-2 and -9, the mediators of enzymatic degradation of the extracellular matrix.
Our studies showing epigenetic silencing of miR-125b contributes to an invasive phenotype provide novel mechanistic insights and identify a potential target mechanism that could be manipulated for therapeutic benefit in HCC.
微小 RNA(miRNA)是一类小的非编码 RNA,可以通过翻译抑制或 mRNA 降解来调节基因表达。我们的目的是评估异常表达的 miRNA 在肝细胞癌(HCC)中的作用。
通过 qPCR 阵列和 Taqman miRNA 检测评估 HCC 组织和细胞中的 miRNA 表达。使用商业检测定量评估细胞增殖、迁移、侵袭和血管生成指数。通过实时 PCR 分析定量评估 DNA 甲基化状态、基质金属蛋白酶(MMPs)mRNA 表达。
miRNA 谱分析发现 HCC 肿瘤组织和细胞系中 miR-125b 的表达降低。在 HCC 细胞中,甲基化抑制剂 5-氮杂-2'-脱氧胞苷可显著增加 miR-125b 的表达,但在正常对照中则不会,这表明 miR-125b 的表达可以通过表观遗传调节。甲基化特异性 PCR 显示 HCC 细胞中 miR-125b 的甲基化状态呈高甲基化。在 HCC 细胞系中引入 miR-125b 前体可显著降低细胞增殖、锚定非依赖性生长、细胞迁移、侵袭和血管生成。生物信息学分析鉴定胎盘生长因子是 miR-125b 的靶标,并通过荧光素酶报告基因构建体实验验证。在 HCC 细胞中过表达 miR-125b 可降低 PIGF 表达,并改变血管生成指数。此外,miR-125b 的调节还改变了 MMP-2 和 MMP-9 的表达,这是细胞外基质酶解的介质。
我们的研究表明 miR-125b 的表观遗传沉默导致侵袭表型,为 HCC 提供了新的机制见解,并确定了一种潜在的治疗靶点机制,可用于治疗获益。